Literature DB >> 22407484

γ-Glutamylamines and neurodegenerative diseases.

Thomas M Jeitner1, Kevin Battaile, Arthur J L Cooper.   

Abstract

Transglutaminases catalyze the formation of γ-glutamylamines utilizing glutamyl residues and amine-bearing compounds such as lysyl residues and polyamines. These γ-glutamylamines can be released from proteins by proteases in an intact form. The free γ-glutamylamines can be catabolized to 5-oxo-L-proline and the free amine by γ-glutamylamine cyclotransferase. Free γ-glutamylamines, however, accumulate in the CSF and affected areas of Huntington Disease brain. This observation suggests transglutaminase-derived γ-glutamylamines may play a more significant role in neurodegeneration than previously thought. The following monograph reviews the metabolism of γ-glutamylamines and examines the possibility that these species contribute to neurodegeneration.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22407484      PMCID： PMC3491119          DOI： 10.1007/s00726-011-1209-3

Source DB:  PubMed          Journal:  Amino Acids        ISSN： 0939-4451            Impact factor:   3.520


  99 in total

1.  Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2.

Authors:  Y C Choi; G T Park; T S Kim; I N Sunwoo; P M Steinert; S Y Kim
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

2.  Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease.

Authors:  Steven M Singer; Gina M Zainelli; Maryam A Norlund; John M Lee; Nancy A Muma
Journal:  Neurochem Int       Date:  2002-01       Impact factor: 3.921

3.  N(epsilon)-(gamma-L-glutamyl)-L-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington's disease.

Authors:  T M Jeitner; M B Bogdanov; W R Matson; Y Daikhin; M Yudkoff; J E Folk; L Steinman; S E Browne; M F Beal; J P Blass; A J Cooper
Journal:  J Neurochem       Date:  2001-12       Impact factor: 5.372

Review 4.  Potential of transglutaminase 2 as a therapeutic target.

Authors:  Daniela Caccamo; Monica Currò; Riccardo Ientile
Journal:  Expert Opin Ther Targets       Date:  2010-09       Impact factor: 6.902

5.  gamma-Glutamylcyclotransferase from rat kidney.

Authors:  A Meister
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

6.  Transglutaminase: mechanistic features of the active site as determined by kinetic and inhibitor studies.

Authors:  J E Folk; P W Cole
Journal:  Biochim Biophys Acta       Date:  1966-08-10

7.  Spectrophotometric assays for L-lysine alpha-oxidase and gamma-glutamylamine cyclotransferase.

Authors:  Jedidah W Danson; Mary Lynn Trawick; Arthur J L Cooper
Journal:  Anal Biochem       Date:  2002-04-15       Impact factor: 3.365

8.  A novel function for transglutaminase 1: attachment of long-chain omega-hydroxyceramides to involucrin by ester bond formation.

Authors:  Z Nemes; L N Marekov; L Fésüs; P M Steinert
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

9.  Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase.

Authors:  Marios Hadjivassiliou; Pascale Aeschlimann; Alexander Strigun; David S Sanders; Nicola Woodroofe; Daniel Aeschlimann
Journal:  Ann Neurol       Date:  2008-09       Impact factor: 10.422

10.  Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content?

Authors:  A Kastner; E C Hirsch; O Lejeune; F Javoy-Agid; O Rascol; Y Agid
Journal:  J Neurochem       Date:  1992-09       Impact factor: 5.372
View more
  4 in total

1.  Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.

Authors:  Ashish Kumar; Andrew Kneynsberg; Janusz Tucholski; Giselle Perry; Thomas van Groen; Peter J Detloff; Mathieu Lesort
Journal:  Exp Neurol       Date:  2012-06-12       Impact factor: 5.330

Review 2.  Cystamine and cysteamine as inhibitors of transglutaminase activity in vivo.

Authors:  Thomas M Jeitner; John T Pinto; Arthur J L Cooper
Journal:  Biosci Rep       Date:  2018-09-05       Impact factor: 3.840

3.  Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL).

Authors:  Shan He; Einat Granot-Hershkovitz; Ying Zhang; Jan Bressler; Wassim Tarraf; Bing Yu; Tianyi Huang; Donglin Zeng; Sylvia Wassertheil-Smoller; Melissa Lamar; Martha Daviglus; Maria J Marquine; Jianwen Cai; Thomas Mosley; Robert Kaplan; Eric Boerwinkle; Myriam Fornage; Charles DeCarli; Bruce Kristal; Hector M Gonzalez; Tamar Sofer
Journal:  Alzheimers Dement (Amst)       Date:  2022-02-23

4.  Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology.

Authors:  Luca Marsili; Jennifer Sharma; Alberto J Espay; Alice Migazzi; Elhusseini Abdelghany; Emily J Hill; Kevin R Duque; Matthew C Hagen; Christopher D Stephen; Gabor G Kovacs; Anthony E Lang; Marios Hadjivassiliou; Manuela Basso; Marcelo A Kauffman; Andrea Sturchio
Journal:  Int J Mol Sci       Date:  2021-07-07       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.